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INTRODUCTION
Panic disorder, which is classified as an anxiety disorder in 
Diagnostic and Statistical Manual of Mental Disorders, 4th ed. 
(DSM-IV), is a severe psychiatric disorder associated with sig-
nificant impairment of the patients’ quality of life as well as their 
social life function. Lifetime prevalence of panic disorder var-
ies 1 to 3 percent of the general population. It is a chronic and 
often disabling anxiety disorder. Panic disorder has panic attacks 
in its clinical presentation.
Although important neurobiological investigations have been 
made, our knowledge on its pathophysiology has not been 
enough yet. On the other hand, there are very limited neuroim-
aging investigations in panic disorder. Most studies
1-11 and Gor-
man’s hypothesis
12 suggest that the aberrancies in structure or 
function in prefrontal cortex, ACC, amygdala, hippocampus 
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may be closely related to the pathophysiology of panic disorder. 
As for the functional brain investigations in panic disorder, 
first of all, we should mention about proton magnetic reso-
nance spectroscopy (
1H MRS) which was also used in the pres-
ent investigation. MRS is a safe and non-invasive means of 
measuring the brain chemistry and metabolism in vivo and has 
an increasing trend in the investigations of neuroimaging of 
psychiatric disorders. In MRS, following neurochemicals had 
been measured; N-acetyl-l-aspartate (NAA; a marker of neu-
ronal viability), glutamate and glutamine, choline (CHO; a 
marker of cell membrane turnover), myo-inositol, and creatine 
(CRE; a marker of cellular energy). Because a reduction of brain 
NAA is considered to reveal a loss of neurons and axons and/or 
neural dysfunction, with its effect on the neuronal integrity and 
viability one can be speculate that its more sensitivity to neuro-
nal loss than structural magnetic resonance imaging (MRI) find-
ings.
13 Although several studies in patients with panic disorder 
revealed inconsistent results, dysregulation of the hypothalam-
ic-pituitary-adrenal (HPA) axis may play a role in panic disor-
der.
14 Hippocampus, a glucocorticoid feedback area, is highly 
sensitive to endogenous glucocorticoid levels and so is an im-
portant region affected by stress modulation organized by the 
hypothalamo-pituitary-adrenal axis (HPA).
15-17 On the other 
hand, Massana et al.
18 performed a MRS study in patients with 
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panic disorder and found that the concentration of creatine and 
phosphocreatine was significantly lower in the right medial 
temporal lobe region of panic disorder patients compared to 
healthy subjects while no significant differences between the 
two groups were observed in the medial prefrontal cortex. 
Moving from this point, as part of a larger effort to further char-
acterize the role of the hippocampus in panic disorder which 
has been already emphasized,
12 we performed a MRS investiga-
tion in which following neurochemicals had been measured; 
NAA (a marker of neuronal viability), CHO (a marker of cell 
membrane turnover), CRE (a marker of cellular energy) in hip-
pocampus of the patients with panic disorder and hypothesized 
that hippocampal neurochemicals would change in this group 
of patients compared to healthy persons. 
METHODS
Patients were selected among those with panic disorder ac-
cording to DSM-IV belonging to our another unpublished 
study. Thus, 20 patients were invited to participate in the pres-
ent study and seventeen accepted. The Structured Clinical In-
terview for the DSM-IV (SCID)
19 and the Hamilton Depres-
sion Rating Scale (HDRS), which determines the severity of the 
depressive symptoms,
20 and Panic Agoraphobia Scale (PAS)
21 
were used to assess participants. The patients were initially 
screened for potential inclusion in the present study before be-
ing further screened for inclusion in the MRS study. Healthy 
volunteers were recruited from the hospital staff. This study was 
carried out under guidelines of Helsinki Declaration. Written 
informed consent was obtained from all subjects. 
The subjects were excluded if any of them have the presence 
of any current comorbid psychiatric disorder apart from depres-
sive disorder, current medical problems, or alcohol/substance 
abuse within the 6 months preceding the study. Of the patients, 
two met criteria for major depressive disorder while following 
lifetime comorbidities were determined: social anxiety disorder 
(n=1), hypochondriasis (n=1), and obsessive compulsive disor-
der (n=1). Matched controls were selected among those who had 
no DSM-IV Axis I disorders in self or in a first-degree relative, 
as determined by the SCID non-patient version, no current medi-
cal problems, neurologic or psychiatric histories, and no use of 
psychoactive medication.  
MRI procedure
Magnetic resonance imaging was conducted at the Firat Uni-
versity Hospital, Department of Radiology, Center of Neuro-
radiology at a 1.5-Tesla GE signa Excite high speed scanner (Mil-
wakuee, USA). With the following parameters, MRI scans were 
obtained: repetition time (TR)=2000 ms, echo time (TE)=15.6 
ms, field of view (FOV)=240 mm, flip angle=20°, bandwidth= 
20.8, slice thickness=2.4 mm, echo spacing=15.6 ms, 8 echoes, 
matrix size=240, and resolution=0.9375×0.9375×2.4 mm. In ad-
dition, hippocampus tracings were performed in according to 
with our another study,
22 with the GE Volume Viewer voxtool 
4.2 program and to with standard anatomic atlases.
23,24 For MRS 
evaluations, the method administered by Bertolino et al.
25 was 
used. Afterwards, NAA, CRE, and CHO levels were investigat-
ed. NAA, CHO, and CRE peaks were determined automatical-
ly for all voxels which were included within the hippocampus. 
Otherwise they were removed. Consequently, for only on vox-
els containing 
1H spectra, final calculations were carried out. 
Position of hippocampal voxels and sample magnetic resonance 
spectrum are presented in Figure 1.
Statistical analysis
All analyses were conducted using the SPSS for Windows 
software, version 13.0 (SPSS Inc., Chicago, IL, USA). A two-
tailed statistical significance level was set at p<0.05 for all anal-
Figure 1. Position of hippocampal voxels and sample magnetic 
resonance spectrum.M Atmaca et al. 
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yses. The differences between patients and controls tested sepa-
rately by a one-way analysis of variance (ANOVA), with 
hemisphere (left or right) as the within-group factor and diag-
nosis as the between-group factor were determined for me-
tabolyte ratios. Categorical data were assessed by using chi-
square test while group differences in demographic variables 
involving continuous data were computed using independent t-
test. For correlations, Pearson’s correlation test was used. 
RESULTS
As presented in Table 1, there were no significant differenc-
es in demographic variables of age, gender composition, edu-
cational level, and handedness between the patients with panic 
disorder and comparison subjects. Furthermore, no structural 
abnormalities were noted qualitatively on the MRI scans of the 
patients or controls. It was also demonstrated the the results of 
hippocampus 
1H MRS forthe patients and healthy volunteers.
When NAA values were compared between groups, statisti-
cally significant difference was detected for both sides (patients, 
mean±SD=430.00±252.62; controls, mean±SD=952.76± 
107.51; t=-7.85, p<0.001 for left side; patients, mean±SD= 
397.18±123.41; controls, mean±SD=832.82±124.14; t=-10.26, 
p<0.001 for right side). In regard to totally NAA, the difference 
was maintained (patients, mean±SD=827.17±330.92; con-
trols, mean±SD=1785.59±144.03; t=-10.95, p<0.001). With re-
spect to CHO levels, statistically significant difference was de-
tected for both sides (patients, mean±SD=430.00±252.62; 
controls, mean±SD=952.76±107.51; t=-7.85, p<0.001 for left 
side; patients, mean±SD=397.18±123.41; controls, mean±SD= 
832.82±124.14; t=-10.26, p<0.001 for right side). The differ-
ence for total CHO was maintained (patients, mean±SD= 
827.17±330.92; controls, mean±SD=1785.59±144.03; t=-10.95, 
p<0.001). As for the CRE values, same diferences were detect-
ed. The mean CRE levels of the patient group was statistically 
significant lower compared to that of control ones (patients, 
mean±SD=430.00±252.62; controls, mean±SD=952.76± 
107.51; t=-7.85, p<0.001 for left side; patients, mean±SD= 
397.18±123.41; controls, mean±SD=832.82±124.14; t=-10.26, 
p<0.001 for right side). Likewise, total CRE was lower in the 
patients than control subjects (patients, mean±SD=827.17± 
330.92; controls, mean±SD=1785.59±144.03; t=-10.95, p<0.001). 
When general linear model was used, age and TBV corrected 
NAA levels were significantly lower in patients compared to con-
trols, with a main effect of diagnosis (F=10.24, p=0.003) and with-
out a main effect of age (F=1.43, p=0.24) and TBV (F=2.04, p= 
0.16). In addition, CHO values were significantly lower in the 
patients compared to controls, with a main effect of diagnosis 
(F=5.70, p=0.024) and without a main effect of age (F=0.14, 
p=0.71) and TBV (F=0.021, p=0.89). Likewise, CRE values were 
significantly lower in patients compared to controls, with a main 
effect of diagnosis (F=13.03, p=0.001) and without a main effect 
of age (F=0.39, p=0.54) and TBV (F=0.59, p=0.45). The mean 
hippocampus NAA/CRE ratio of the patients did not differ to 
that of control subjects (patients, mean±SD=1.34±0.35; con-
trols, mean±SD=1.42±0.18; t=-0.81, p=0.42). Likewise, NAA/
CHO ratio of the patients with panic disorder did not differ that 
of the control subjects, as determined by unpaired t test (pa-
tients, mean±SD=0.93±0.24; controls, mean±SD=1.04±0.10; 
t=-0.64, p=0.11). On the other hand, no significant difference 
was detected between groups in regard to CHO/CRE ratio 
(patients, mean±SD=1.46±0.27; controls, mean±SD=1.37± 
0.18; t=1.06, p=0.29). NAA, CHO, or CRE values were did not 
correlate with hippocampus volumes, HDRS or PAS scores. 
DISCUSSION
In the present study, we found some important findings. 
When NAA, CHO and CRE values were compared between 
groups, statistically significant lower levels for all ones were de-
tected for both sides. This change is independent of volumes 
because of the fact that there was no volume difference between 
groups for both sides and that no correlation was found be-
tween NAA, CHO, or CRE values and hippocampus volumes. 
At this point, we require to mention about our previous investi-
gations in a variety of psychiatric disorders on NAA. In the other 
studies of ours, it was showed that NAA might also play an im-
portant role on the pathophyiology of bipolar disorder and ob-
sessive compulsive disorder (OCD), and on the neuroprotec-
Table 1. Demographic, clinical, volumetrik and spectroscopic and 
1H MRS data of the patients and controls
Patients (N=20) Controls (N=20)
Age 33.41±6.95    31.71±5.5800
Gender (F/M) 10/8 9/9
Duration (years) 03.65±2.53 -
Education (years)  08.29±3.65   8.94±3.510
Handedness (right) 20 20
HDRS score 11.11±4.78  05.82±2.40*
Hippocampus volume (mm
3)
Left  3060.32±390.64   2987.72±266.7200
Right 3123.03±299.80   3026.14±237.0900
NAA 0827.17±330.92 1785.59±144.03*
CHO 0946.24±451.80  1725.24±145.92* 
CRE 0641.35±246.41 1269.24±130.39*
No significant differences exist between groups in age, handed-
ness, education, and gender composition. *p<0.001. F: female, M: 
Male, HDRS: Hamilton Depression Rating Scale, NAA: N-acetyl 
aspartate, CHO: choline, CRE: creatine, 
1H MRS: proton magnetic 
resonance specroscopy164  Psychiatry Investig 2012;9:161-165
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tive effect of quetiapine.
26-28 These findings are very important 
since the role of NAA is established in neuronal integrity. Dis-
ablement in neuronal integrity may be associated with a neu-
rodegenerative process and this may be related to the patho-
genesis of panic disorder. Despite several investigations in 
patients with panic disorder revealed inconsistent results, dys-
regulation of the hypothalamic-pituitary-adrenal (HPA) axis 
may play a role in panic disorder.
14 Hippocampus, a glucocor-
ticoid feedback area, is highly sensitive to endogenous gluco-
corticoid levels and so is an important region affected by stress 
modulation organized by the hypothalamo-pituitary-adrenal 
axis (HPA).
15-17 In this context, there may be an association be-
tween HPA dysregulation and hippocampus neurochemicals. 
There is only one study on hippocampal neurochemicals in the 
patients with panic disorder.
28 In their study, Trzesniak et al.
28 
comprised 25 panic patients and 18 healthy control subjects 
and found that compared with controls, panic patients demon-
strated significantly lower NAA/CRE in the left hippocampus. 
They suggested that left hippocampal NAA/CRE in panic dis-
order might be reflecting neuronal loss or neuronal metabolic 
dysfunction in that disorder, as discussed by us.
As for the CHO and CRE values, we found significantly re-
duced levels for both neurochemicals in the patients with panic 
disorder in contrast to the study performed by Trzesniak et al.
29 
who did not detected any CHO difference between panic pa-
tients and healthy control subjects. On the other hand, they 
found significant lower NAA/CRE ratio in the right hippocam-
pus. We did not the exact reason between the findings of their 
study and ours. However, some confounding factors may con-
tribute to this discrepancy. First of all, in their study, the mean 
age of the patients (39.2±9.9) is considerably higher than that 
of the present study (33.41±6.95). Secondly, in their study, six-
teen of the patients were receiving pharmacological treatment 
at the time of MRI scanning. It was shown phosphotidylcho-
line breakdown to have an important role in signal transduc-
tion
30 suggesting that reduced CHO concentrations in patients 
with panic disorder might contribute to the pathophysiology 
of the disorder by this way. Reduced CRE values were also re-
ported by Massana et al.
18 who found that the concentration of 
creatine and phosphocreatine was significantly lower in the 
right medial temporal lobe region of panic disorder patients 
compared to healthy subjects, without any significant differ-
ences for the medial prefrontal cortex and concluded that these 
results provided neurochemical evidence suggesting the in-
volvement of the amygdalohippocampal region in the patho-
genesis of panic disorder. Our same finding in the present 
study was important when we take into consideration that as 
implicated by Trzesniak et al.,
29 CRE is thought to be relatively 
stable among individuals and in most brain areas; for this rea-
son, it is often used as an internal reference. In the present study, 
absolute NAA, CHO, and CRE meaurements were discussed 
rather than metabolite ratios. The main reason why we done 
such a thing that NAA metabolite ratios must explain the alter-
ations in the CRE reference peak that make out of vogue their 
usefulness as an internal reference for the other metabolite 
peaks.
31,32
Several limitations exist with the present study. First of all, 
our sample size is small. This may limit the generalizability of 
our findings to all panic patients. Second, we only evaluated hip-
pocampal region, however, some other important anatomic re-
gions should be incuded in 
1H MRS studies on panic disorder. 
Consequently, in the present study we found that NAA, 
CHO and CRE values of the patients with panic disorder were 
lower than those healthy controls. Future studies involving a 
large number of panic patients may shed further light on the 
generalizability of the current findings to persons with panic 
disorder. 
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